Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lirilumab + nivolumab + azacitidine
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination therapy regimen consists of lirilumab, nivolumab, and azacitidine, and is primarily investigated for the treatment of myelodysplastic syndromes (MDS). Lirilumab is an investigational human IgG4 monoclonal antibody that blocks killer immunoglobulin-like receptors (KIR) on natural killer (NK) cells, thereby enhancing their anti-tumor activity. Nivolumab is a programmed death-1 (PD-1) checkpoint inhibitor that activates T-cell-mediated immune responses. Azacitidine is a hypomethylating agent that exerts antineoplastic effects by inducing DNA hypomethylation and direct cytotoxicity on abnormal hematopoietic cells. The combination aims to synergistically enhance immune surveillance against MDS cells by simultaneously targeting inhibitory signals on both NK and T cells while utilizing the epigenetic modulating effects of azacitidine.
- Brand names
- OpdivoVidaza
- Other names
- Lirilumab and Nivolumab with AzacitidineL-M.D. Anderson Cancer Center-myelodysplastic syndrome
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)KIR2DS2 (Killer cell immunoglobulin-like receptor, two Ig domains and short cytoplasmic tail 2)KIR2DS1 (Killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 1)KIR2DL2 (Killer cell immunoglobulin-like receptor 2DL2)DNAKIR2DL1KIR2DL3DNMT1 (DNA (cytosine-5)-methyltransferase 1)
Beyond the preview
Go deeper on lirilumab + nivolumab + azacitidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lirilumab + nivolumab + azacitidine.